Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
2007

Comparing Budesonide/Formoterol Inhalers for Asthma Treatment

Sample size: 680 publication 10 minutes Evidence: high

Author Information

Author(s): Morice A H, Peterson S, Beckman O, Osmanliev D

Primary Institution: University of Hull

Hypothesis

Is the new HFA pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol more effective than existing inhalers?

Conclusion

Both the HFA pMDI and DPI formulations of budesonide/formoterol are effective and well-tolerated treatments for asthma.

Supporting Evidence

  • Budesonide/formoterol pMDI showed a significant increase in morning PEF compared to budesonide pMDI.
  • Both budesonide/formoterol therapies improved asthma symptoms more than budesonide pMDI.
  • Patients reported similar health-related quality of life improvements with both budesonide/formoterol devices.

Takeaway

This study looked at different inhalers for asthma and found that a new type works just as well as the older ones.

Methodology

A 12-week, multinational, randomised, double-blind, double-dummy study involving patients aged ≥ 12 years with asthma.

Limitations

The study did not include a clinical trial registration identifier as it began enrolment before the required date.

Participant Demographics

Patients aged 12 years and older, with a mix of genders and a range of asthma severity.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI: −10.4 to 4.9

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1111/j.1742-1241.2007.01574.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication